Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / BNTX
Stock rating
BioNTech SE (BNTX) Stock Rating & Analysis
As of October 6, 2026, MELANY rates BioNTech SE 67 out of 100 (Promising).
MELANY ratingRated 2026-10-06BNTX · composite score
About BioNTech SE
BioNTech is a Germany-based biotechnology company developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases such as covid. Its oncology pipeline spans several drug classes, including mRNA-based drugs encoding antigens and neoantigens, monospecific and bispecific antibodies, and antibody-drug conjugates (ADCs). Its first commercialized product is Comirnaty, the covid vaccine partnered with Pfizer.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why BNTX scores 67/100
BNTX's 8 factor scores run from 50 to 80, and 3 of them sit above its composite of 67. Here is how BNTX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- PEG ratio 0.05 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 77%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Earnings in 28 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 28 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BNTX compares
As of October 7, 2026, BioNTech SE is tied for 7th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for BNTX
- Operating margin -807%, currently unprofitable on a trailing basis
- Negative free cash flow, company consuming cash, not generating it
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
BioNTech SE sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 60/100 for strength. Theme strength feeds BNTX's momentum and catalyst factors above.
BNTX trade plan (Pro)
MELANY has a full position plan for BioNTech SE: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BNTX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. BioNTech SE's 67/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BNTX
Is BioNTech SE (BNTX) a buy?
As of 2026-10-06, MELANY rated BioNTech SE Promising with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is BioNTech SE's MELANY score?
BioNTech SE (BNTX) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BNTX stock rating calculated?
MELANY scores BNTX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy BioNTech SE stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates BioNTech SE (BNTX) Promising with a composite of 67/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BNTX stock price forecast?
MELANY does not publish price targets or forecasts for BNTX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for BioNTech SE, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BNTX stock overvalued or undervalued?
MELANY's valuation factor currently reads 77/100 for BioNTech SE, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BNTX's read.
What price should I buy BNTX at?
Rather than chasing the current price, MELANY computes a smart entry zone for BNTX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BNTX stock?
The top risks MELANY currently flags for BioNTech SE: Operating margin -807%, currently unprofitable on a trailing basis; Negative free cash flow, company consuming cash, not generating it; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is BioNTech SE a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 50/100 for BioNTech SE, and earnings track record, at 50/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BNTX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for BNTX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BNTX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BNTX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BNTX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.